Exopharm Ltd

Exopharm's mission is to be a leader in the field of clinical human therapeutics using exosomes or extracellular vesicles (EV's).
Exopharm is an Australian regenerative medicine biopharmaceutical company that will develop and commercialise EV's as therapeutic agents. Plexaris™, a platelet-derived EV medicine, is currently in human trials for wound repair and will eventually include indications associated with age-related mobility treatments. Its MSC-sourced EVs product Cevaris™ is expected to enter human trials next in age-related sensory degeneration applications. Exopharm's engineered EV products are in proof-of-concept stage, led by Fortrexo™, a novel approach to treating coronavirus.
Exopharm's core technology involves the isolation, purification, and engineering of EVs. Exopharm's LEAP Technology has been developed to address the existing limitations in exosome purification processes and gives Exopharm the opportunity to unlock the potential of EV's as a new generation medical treatments.

Melbourne, Melbourne, VIC AU